Defence Therapeutics and Orano agree to collaborate on radio-immuno-conjugates

Under the agreement, Defence will develop the first radio-immuno-conjugate therapy based on an Auger electron emitter by combining Defence’s intracellular targeting and radiochemistry expertise provided by Orano SA, a world-renowned multinational company based in Chatillon, France.

Alethia Biotherapeutics Announces Receipt of FDA Authorization to Begin Phase 2 Development for its EMT Inhibitor, AB-16B5

Alethia Biotherapeutics announced today that the U.S. Food and Drug Administration has cleared its Phase 2 Investigational new drug (IND) application for AB-16B5, a potent inhibitor of the epithelial to mesenchymal transition (EMT).

NewsGuest UserMay 21, 2020alethia biotherapeutics, cancer treatment, phase 2

Canadian collaboration to accelerate development of cancer treatments

The goal of this collaboration is to identify the most promising antibodies, and increase their value by generating data that effectively de-risks each asset.